ANIX on Nasdaq
Anixa Biosciences Inc
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Nexentis Technologies Inc., Clene Inc. or NOMAD POWER SOLUTIONS, INC., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2024
Where the money goes
Where each dollar of revenue went, fiscal 2024
- Research and development100¢$6.4M
Out of $210.0K in revenue.43 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-10-31 | 2024-10-31 |
|---|---|---|
| Research and development expenses (including non-cash stock-based compensation expenses of $1,560 and $1,859, respectively) | $5.1M | $6.4M |
| General and administrative expenses (including non-cash stock-based compensation expenses of $2,250 and $2,923, respectively) | $6.6M | $7.4M |
| Total operating costs and expenses | $11.7M | $13.8M |
| Loss from operations | -$11.7M | -$13.8M |
| Interest income | $673.0K | $1.1M |
| Net loss | -$11.0M | -$12.7M |
| Less: Net loss attributable to noncontrolling interest | -$101.0K | -$144.0K |
| Net loss attributable to common shareholders | -$10.9M | -$12.6M |
| Basic | -$0.34 | -$0.39 |
| Diluted | -$0.34 | -$0.39 |
| Basic | 32.5K shares | 31.9K shares |
| Diluted | 32.5K shares | 31.9K shares |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-10-31 | 2024-10-31 | 2023-10-31 |
|---|---|---|---|
| Cash and cash equivalents | $1.2M | $1.3M | |
| Shortterm investments | $13.9M | $18.7M | |
| Receivables | $173.0K | ||
| Prepaid expenses and other current assets | $713.0K | $1.3M | |
| Total current assets | $15.9M | $21.4M | |
| Operating lease right-of-use asset | $193.0K | $229.0K | |
| Total assets | $16.1M | $21.6M | |
| Accounts payable | $165.0K | $525.0K | |
| Accrued expenses | $1.8M | $1.9M | |
| Operating lease liability | $41.0K | $29.0K | |
| Total current liabilities | $2.0M | $2.5M | |
| Operating lease liability, non-current | $163.0K | $203.0K | |
| Total liabilities | $2.1M | $2.7M | |
| Common stock, par value $.01 per share; 100,000,000 shares authorized; 33,013,829 and 32,196,862 shares issued and outstanding as of October 31, 2025 and 2024, respectively | $330.0K | $322.0K | |
| Additional paid-in capital | $266.5M | $260.4M | |
| Accumulated deficit | -$251.7M | -$240.8M | |
| Treasury stock, 2,000 shares at cost as of October 31, 2024 | -$6.0K | ||
| Total shareholders equity | $15.2M | $20.0M | |
| Noncontrolling interest (Note 2) | -$1.2M | -$1.1M | -$966.0K |
| Total equity | $13.9M | $18.9M | $23.4M |
| Total liabilities and equity | $16.1M | $21.6M | |
| Preferred stock, par value | $100.00 | $100.00 | |
| Preferred stock, shares authorized | 19.9K shares | 19.9K shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares | |
| Common stock, par value | $0.01 | $0.01 | |
| Common stock, shares authorized | 100.0M shares | 100.0M shares | |
| Common stock, shares issued | 33.0M shares | 32.2M shares | |
| Common stock, shares outstanding | 33.0M shares | 32.2M shares | |
| Treasury stock, common shares | 2.0K shares | 2.0K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-10-31 | 2024-10-31 |
|---|---|---|
| Net loss | -$11.0M | -$12.7M |
| Stock option compensation to employees and directors | $3.7M | $4.4M |
| Stock options issued to consultants | $129.0K | $125.0K |
| Common stock issued to consultants | $255.0K | |
| Amortization of operating lease right-of-use asset | $36.0K | $37.0K |
| Amortization of discount on held-to-maturity securities | -$143.0K | |
| Receivables | $173.0K | $97.0K |
| Prepaid expenses and other current assets | $552.0K | -$23.0K |
| Accounts payable | -$360.0K | $319.0K |
| Accrued expenses | -$185.0K | $176.0K |
| Operating lease liability | -$28.0K | -$43.0K |
| Net cash used in operating activities | -$7.2M | -$7.3M |
| Disbursements to acquire short-term investments | -$44.4M | -$63.8M |
| Proceeds from maturities of short-term investments | $49.2M | $68.0M |
| Net cash provided by investing activities | $4.9M | $4.3M |
| Proceeds from sale of common stock in an at-the-market offering, net of offering expenses of $183 and $168, for the years ended October 31, 2025 and 2024, respectively | $2.4M | $3.0M |
| Proceeds from sale of common stock pursuant to employee stock purchase plan | $7.0K | $10.0K |
| Net (costs) proceeds from exercise of stock options | -$105.0K | $456.0K |
| Disbursements for purchases of treasury stock | -$6.0K | |
| Net cash provided by financing activities | $2.3M | $3.4M |
| Net (decrease) increase in cash and cash equivalents | -$27.0K | $356.0K |
| Cash proceeds from interest income | $686.0K | $1.2M |
| Modification to operating lease right-of-use asset | -$100.0K | |
| Modification to operating lease liability | $100.0K | |
| Offering expenses | $183.0K | $168.0K |
Former names
Recent filings
- Sep 30, 20264
- Sep 28, 20264
- Sep 28, 20264
- Sep 25, 20264
- Sep 14, 20264
- Sep 14, 20264
- Sep 11, 20264
- Sep 9, 202610-Q
- Aug 3, 20264
- Jul 29, 20264
- Jul 28, 20264
- Jul 27, 20264
- Jul 27, 20264
- Jul 21, 20264
- Jul 20, 20264
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11